Clinical Trials Logo

Mucositis clinical trials

View clinical trials related to Mucositis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06186700 Active, not recruiting - Clinical trials for Breast Cancer Female

Effect of Pentoxifylline on Preventing Chemotherapy-induced Mucositis in Patients With Breast Cancer

Start date: December 25, 2023
Phase: Phase 2
Study type: Interventional

This clinical trial is a randomized controlled trial that aims to assess the usefulness of adding pentoxifylline to the neoadjuvant chemotherapy treatment protocol of doxorubicin/cyclophosphamide for breast cancer patients to decrease the incidence of developing oral mucositis, downgrade the mucositis symptoms, alleviate the associated pain using the visual analogue scale, and enhance the quality of patient life using the EQ-5D-3L questionnaire. The participant will administer Pentoxifylline oral tablets three times per day along with the treatment protocol, starting from the first doxorubicin/cyclophosphamide cycle till the end of the fourth cycle. The researchers will compare the mucositis incidence and grade in the presence or absence of oral pentoxifylline.

NCT ID: NCT06117904 Active, not recruiting - Mucositis Clinical Trials

Adjunctive Treatments for the Prevention of Radiotherapy-Induced Mucositis

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Radiation therapy (RT) is used in at least 50% of cancer patients and is critical in treating and palliating tumor-related symptoms. Normal tissue radiation toxicity remains an overwhelming obstacle in treating cancer patients with localized tumors. Mucositis is the inflammation and ulceration of the oral and gastrointestinal mucosa observed with different cancer therapies. Oral mucositis is a common, severe, and debilitating complication of RT occurring several days to weeks after RT initiation.

NCT ID: NCT05913895 Active, not recruiting - Pain Clinical Trials

The Effect of Hydrogen Water in Oral Mucositis in Head and Neck Cancer Patients After Therapy

Start date: December 24, 2023
Phase: N/A
Study type: Interventional

Inpatients or outpatients diagnosed with head and neck cancer who met the inclusion and exclusion criteria were referred to the co-investigator(Dr. Chih-Jen Huang and Dr. Hui-Ching Wang), who then personally explained to each participant, the purpose and conduct of the study, so that they all understood their rights and interests before giving a written consent.

NCT ID: NCT05834946 Active, not recruiting - Periodontitis Clinical Trials

Biological Responses Affecting Early-stage Dental Implant Placement in Patients With History of Periodontitis

Start date: March 4, 2021
Phase: N/A
Study type: Interventional

This prospective parallel, double-blind, four-arm randomised controlled clinical study is planned to assess the difference in the level of the inflammatory biomarkers expressed following the placement of the first dental implant in patients with history of periodontitis (successfully treated) and healthy controls without the disease, during implant osseointegration period. The subjects in both groups will also be randomised to receive one of the two types of implants provided which have different surface treatment.

NCT ID: NCT05669521 Active, not recruiting - Mucositis Clinical Trials

Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690

Start date: June 15, 2022
Phase: Phase 2
Study type: Interventional

Patients expected to receive a 500 mg/m2 of Leucovorin by iv & 500 mg/m2 of Fluorouracil (5FU) by iv bolus for their Colorectal Cancer. The patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization at 5 hours & 11 hours post 5-FU iv bolus. This treatment cycle will continue weekly for 6 weeks. The TK112690 dose will be 45 mg/kg.

NCT ID: NCT05658016 Active, not recruiting - Mucositis Clinical Trials

Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690

Start date: June 17, 2022
Phase: Phase 2
Study type: Interventional

Patients expected to receive a continuous course of radiation as single daily fractions of 2.0 Gy treatment with a cumulative radiation dose of 70 Gy. The radiation can be 2DRT, 3DRT,IMRT etc. Prior to each radiation treatment the patients will receive a one-hour infusion of TK-90 or equivalent TK-90 placebo depending on randomization. 6 Hours after the completion of TK-90 infusion or TK-90 placebo dose, the patients will receive another identical TK-90 or TK-90 placebo treatment depending on randomization. This treatment cycle will continue for 7 weeks. The TK112690 dose will be 45 mg/kg.

NCT ID: NCT05493800 Active, not recruiting - Multiple Myeloma Clinical Trials

Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

Capella
Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell transplantation(auto-HSCT).

NCT ID: NCT05254275 Active, not recruiting - Clinical trials for Peri-implant Mucositis

Ozoral Pro and Ozoral Gel vs Chlorhexidine Gel 1% for the Management of Peri-implant Mucositis Sites.

Start date: March 22, 2022
Phase: N/A
Study type: Interventional

This is a randomized controlled clinical trial (RCT) with a split-mouth design. After signing the informed consent, patients satisfying the inclusion criteria will undergo supragingival and subgingival professional oral hygiene of both arches performed with ultrasonic instrumentation with PEEK inserts, manual instrumentation with titanium curettes and air polishing with glycine powder. After that, the following treatment will be randomly assigned: - Ozoral Pro and Ozoral gel administration and home application for 2 peri-implant mucositis sites. - Curasept chlorhexidine gel 1% administration and domiciliary application for 14 days for 2 peri-implant contralateral sites. The study will last 2 years. Patients will be visited at: T0, after 1 month from T0 (T1), after 3 months (T2), after 6 months (T3), after 9 months (T4), after 12 months (T5), after 15 months (T6), after 18 months (T7), after 21 months (T8) and after 24 months (T9). For each time point, (except for T1), professional hygiene will be performed again. At each recall session, the following periodontal clinical indices were collected using a probe on each peri-implant site: BOP, GBI, conditions of the marginal mucosa (swelling and erythema), suppuration, migration of the marginal mucosa, PD, PI ,BS.

NCT ID: NCT04752384 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients

Start date: July 8, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm prospective clinical trial to determine the safety and feasibility of using transdermal buprenorphine in alleviation of radiation induced mucositis pain in head and neck cancer patients.

NCT ID: NCT04685395 Active, not recruiting - Oral Mucositis Clinical Trials

Comparative Efficacy of Rebamipide Gargle And Benzydamine HCL Gargle in Prevention and Management of Chemo- and Radio-therapy-induced Oral Mucositis

Start date: December 26, 2019
Phase: Phase 3
Study type: Interventional

evaluate preventive and therapeutic effects of Rebamipide gargle on reducing incidence of oral mucositis in comparison with benzydamine HCL mouthwash.